

# Spontaneous Corneal Perforation in Premature Infants

J S Wong, V Balakrishnan, K L Tan

## ABSTRACT

**Spontaneous corneal perforation in premature infants not due to birth trauma is a rare event, with only 8 cases reported in the literature. We recently encountered a case of spontaneous corneal perforation in an extremely premature infant born at 26 weeks of gestation. The mechanism leading to this event was corneal exposure resulting in corneal epithelial defect. Clinical evidence of secondary infection ensued and this led to cornea thinning, descemetocoele formation and subsequent perforation with extrusion of intraocular contents. Although other mechanisms were responsible in the previously reported cases, we feel that exposure keratopathy leading to this complication poses a potential hazard to all premature infants. An awareness among care givers of this potential complication together with avoidance of exposure keratopathy in this group of patients is paramount in preventing this visually catastrophic event.**

**Keywords:** premature infants, exposure keratopathy, spontaneous corneal perforation

## INTRODUCTION

Spontaneous corneal perforation in neonates not related to birth trauma is an uncommon event, and is associated with a very grim visual prognosis. To date, only 8 cases of spontaneous corneal perforation in premature infants have been reported in the literature<sup>(1-7)</sup>. Although the exact pathophysiology is unknown, various processes had been described as possible mechanisms leading to this visually catastrophic event. We present a case encountered recently.

## CASE REPORT

An extremely premature pair of male twins were delivered vaginally at 26 weeks of gestation on 22 April 1995. Twin I weighed only 505 gramme at birth and Twin II was a stillborn. The Apgar scores were 3 and 5 at 1 and 5 minutes respectively and the baby was put on ventilatory support. The baby had a patent ductus arteriosus which did not close with 3 doses of indomethacin.

An ophthalmological consult was obtained on 7 days post-delivery because of bilateral haziness of the corneas despite measures to keep the cornea moist. Portable slitlamp examination revealed bilateral

epithelial defect involving 80%-90% of corneal surfaces with purulent discharge in the left side. A corneal swab for culture was obtained. Gentamicin 8 mg/mL and cephazolin 50 mg/mL eyedrops every 2 hourly were administered to the left eye. The right eye was treated with liberal bland ointment lubricants (Duratears) application and artificial tears every half hourly. The cultures were negative.

Eleven days later (20 days of age), spontaneous extrusion of crystalline lens and vitreous prolapse from the left eye occurred. The retina showed folds and there was haemorrhage from the attachment of hyaloid vessels at the optic disc. A small corneal perforation in the centre of cornea was identified and was sealed with cyanoacrylate glue the following morning. Gentamicin eyedrops was then discontinued in view of possible corneal epithelial toxicity; cephazolin eyedrops every 6 hourly and artificial tears ointment were continued.

The perforation remained sealed with a repeat cyanoacrylate glue application 2 days later (the initial glue was dislodged). A repeat culture of corneal surface swab and vitreous content remained negative. On subsequent follow-up the right cornea epithelial defect healed and cornea became clearer. The left cornea developed total vascularisation and the eye became phthisical when reviewed at 27 days of age. Antibiotic eyedrops were stopped a week later.

Unfortunately, the baby developed methicillin resistant *Staphylococcus aureus* septicaemia at about 4 weeks of age and several days later, he developed evidence of necrotising enterocolitis. Despite aggressive treatment, he finally succumbed to the septicaemia and passed away at 6 weeks of age. Postmortem examination of the globes showed a phthisical left eye with scarring response surrounding the old corneal perforation. The right cornea did not reveal any abnormal structural abnormalities.

## DISCUSSION

There are several proposed mechanisms leading to spontaneous corneal perforation in these newborns. A review of the literature showed that underlying structural abnormality such as Peter's anomaly predisposing to a weakened cornea together with increased intraocular pressure were responsible in 5 premature infants<sup>(2,5,6,7)</sup>. Epithelial defect and infectious processes leading to a thinned cornea is thought to be responsible in at least 2 cases<sup>(3,4)</sup>, and

Department of Ophthalmology  
National University Hospital  
5 Lower Kent Ridge Road  
Singapore 119074

J S Wong, MBBS, M Med  
(Ophth), FRCSEd  
Registrar

V Balakrishnan, M Med (Ophth),  
FRCSEd, FRCOphth  
Senior Lecturer

Department of Paediatrics  
National University Hospital

K L Tan, FRCPE, FRACP, DCH  
Professor

Correspondence to:  
Dr J S Wong

one premature baby had necrotising keratitis<sup>(1)</sup>. The timing of perforations ranged from at birth to 39 days of age.

In our case, cornea exposure leading to epithelial defect was the postulated initiating event. Normal lid disjunction occurs at about fifth to sixth months of gestation age<sup>(8)</sup>, and since most premature infants are born after this period, the potential for exposure keratopathy is present in these infants. However, many of such premature infants have adequate lid closure, though one must be on the watch out for those infants who have inadequate lid closure leading to cornea exposure. With the breach of intact epithelium, the natural passive resistance to infection is lost and infective keratitis may supervene. If this is detected early, treatment with antibiotics together with adequate corneal protection may abort the process and the corneal integrity may be retained, although stromal haze and scarring may be the consequence of such an event.

However in some cases, relentless deterioration and corneal thinning leading to a descemetocoele formation may follow. This eventually leads to spontaneous perforation as seen in our case and in previously reported cases. It is possible that due to an immature immune system among the premature infants, natural immune mechanisms in the tear film such as the IgA level, the tear composition, or the tear production be deficient or altered. This may result in the susceptibility of this special group of infants to severe ulcerative keratitis. In our case, the diagnosis of infective keratitis was made clinically, as no positive organisms were identified. Postmortem histological examination did not reveal any underlying structural abnormalities in the adjacent cornea tissue that may

weaken the cornea and hence predispose it to spontaneous perforation.

We feel that neonatologists and paediatric ophthalmologists must be aware of the possibility of this potentially blinding condition in premature infants with exposure keratopathy. Avoidance of corneal exposure is paramount in preventing this condition and all neonates with poor lid closure should be administered liberal ocular lubricants round the clock. Once an epithelial defect has been recognised, aggressive treatment and close follow-up by the paediatric ophthalmologist is imperative.

## REFERENCES

1. Jensen OA. Necrotizing keratitis (keratomalacia) with corneal perforation and expulsive uveal haemorrhage in a newborn. *Acta Ophthalmol* 1968; 46:215-7.
2. Krause U, Koivisto M, Rantakallio P. A case of Peter's syndrome with spontaneous corneal perforation. *J Paediatr Ophthalmol* 1969; 6:145-9, 17:242-44.
3. Michelson PE, Ruff R, Ifthimiadis B. Endogenous Candida endophthalmitis leading to bilateral corneal perforation. *Am J Ophthalmol* 1975; 80:800-2.
4. Backes CR, Makley TA, Rogers GL et al. Spontaneous corneal perforation with expulsion of the lens and retina in a premature infant. *J Paediatr Ophthalmol Strabismus* 1980; 17:242-4.
5. Bachynski BN, Andreu R, Flynn JR. Spontaneous corneal perforation and extrusion of intraocular contents in premature infants. *J Paediatr Ophthalmol Strabismus* 1986; 21:25-8.
6. Varley MP, Grossniklaus HE, Lass JH. Corneal perforation at birth secondary to Peter's anomaly. *Am J Ophthalmol* 1987; 104:303-4.
7. Zigelbaum BM, Stroh EM, Perry HD et al. Corneal perforation in a premature infant. *J Refractive Surg* 1995; 11:96-98.
8. Cook CS, Ozanics V, Jakobiec FA. Prenatal development of the eye and its adnexa. In: Tasman W, Jaeger EA, eds. *Duane's Foundation of Clinical Ophthalmology*. Philadelphia: Lippincott-Raven, 1995: 82.

PLEASE REFER TO FULL DATA SHEET BEFORE PRESCRIBING. VALTRES<sup>™</sup> TABLETS PRESENTATION: White Tablets marked 'VALTRES' and '500' containing 500mg valaciclovir. INDICATIONS: VALTRES is indicated for the treatment of herpes zoster (shingles). VALTRES is indicated for the treatment of herpes simplex infections of the skin and mucous membranes, including initial and recurrent genital herpes. DOSAGE AND ADMINISTRATION: Dosage in adults: for treatment of herpes zoster, 1000mg of VALTRES to be taken 3 times daily for 7 days. For treatment of herpes simplex, 500mg of VALTRES to be taken twice daily. For recurrent episodes, treatment should be for 5 days. For initial episodes, which can be more severe, treatment may have to be extended to 10 days. Dosage in children: No data are available. Dosage in the elderly: dosage modification is not required unless renal function is significantly impaired. Adequate hydration should be maintained. Dosage in renal impairment: The dosage of Valtrex should be modified in patients with severely impaired renal function (See full prescribing information). Dosage in hepatic impairment: Dose modification is not required in patients with mild or moderate cirrhosis (hepatic synthetic function maintained). CONTRA-INDICATIONS: VALTRES is contra-indicated in patients known to be hypersensitive to valaciclovir, acyclovir or any components of formulations of VALTRES. PRECAUTIONS AND WARNINGS: Use in the elderly: Dosage modification is not required in the elderly unless renal function is significantly impaired. Adequate hydration should be maintained. The VALTRES dose should be adjusted in patients with significant renal impairment (See full prescribing information). The results of mutagenicity tests *in vitro* and *in vivo* indicate that valaciclovir is unlikely to pose a genetic risk to humans. Valaciclovir was not carcinogenic in bio-assays performed in mice and rats. Valaciclovir was not teratogenic in rats or rabbits. Valaciclovir did not affect fertility in male or female rats dosed by the oral route. PREGNANCY & LACTATION: There are no data on the use of VALTRES in pregnancy and lactation. VALTRES should only be used in pregnancy if the potential benefits of treatment outweigh the potential risk. DRUG INTERACTIONS: No clinically significant interactions have been identified. Cimetidine and probenecid increase the AUC of acyclovir by reducing its renal clearance; however no dosage adjustment is necessary because of the wide therapeutic index of acyclovir. Other drugs which affect renal physiology could affect plasma levels of acyclovir. ADVERSE REACTIONS: VALTRES was well tolerated when used for the treatment of herpes zoster or herpes simplex in clinical trials. The most commonly reported adverse experiences were mild headache and nausea and these were reported in a similar proportion of patients on valaciclovir, acyclovir and placebo. There are at present no data available on over-dosage with VALTRES. Further information is available on request. Glaxo Wellcome Singapore Pte Ltd, 150 Beach Road, Gateway West #21-00, Singapore 189720. Tel: 2916070. Valtrex<sup>™</sup> and Zovirax<sup>™</sup> are trademarks owned by the Glaxo Wellcome Group of Companies. AV/VAL/TAB/AC/Adv/97/0002 McCANN GSS0202

**GlaxoWellcome**